Milgamma is a drug whose active substance is benfotiamine, a derivative of vitamin B1, an essential substance that plays an important role in the metabolism of the body.
Benfotiamine can be used to provide vitamin B1 deficiencies, caused by excessive alcohol consumption, and also prevents the harmful consequences of increased glucose levels in diabetic patients.
Milgamma is an oral drug produced by the pharmaceutical company Mantecorp Indstria Qu-mica e Pharmaceutica.
Milgamma is indicated for the prevention and treatment of vitamin B1 deficiencies caused by excess alcoholic beverages, as well as in the treatment of symptomatic polyneuropathy associated with diabetes, which manifests itself mainly in the form of pain and tingling in the legs in diabetic and alcoholic patients.
The price of Milgamma ranges from 15 to 48 reais
The way to use Milgamma is to use 1 tablet of 150 mg milgamma, 2 to 3 times a day, to dose 300 mg to 450 mg of benfotiamine per day, depending on the severity of neuropathy, for at least 4 to 8 after this initial period, maintenance treatment should be based on therapeutic response , and it is recommended to take 1 tablet a day, corresponding to 150 mg benfotiamine.
Dosage and dosage of the drug should be indicated by the endocrinologist.
Milgamma side effects may include rashes, hives, anaphylactic reactions and nausea.
Milgamma is counterinditive in patients with hypersensitivity to one of the components of the formula, as well as in pregnant, nursing or under 18-year-olds.